paroxetine has been researched along with Parkinson Disease, Secondary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
| Bayindirli, D; Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M; Vural, G | 1 |
| Chung, YC; Jin, BK; Kim, SR | 1 |
| Allen, SA; Malek-Ahmadi, P | 1 |
| Leo, RJ | 1 |
1 review(s) available for paroxetine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Movement disorders associated with the serotonin selective reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Age Factors; Aged; Akathisia, Drug-Induced; Depressive Disorder; Dyskinesia, Drug-Induced; Dystonia; Female; Fluoxetine; Fluvoxamine; Humans; Male; MEDLINE; Middle Aged; Parkinson Disease, Secondary; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; United States | 1996 |
4 other study(ies) available for paroxetine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |
Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Morpholines; Parkinson Disease, Secondary; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2010 |
Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Brain; Dopamine; Enzyme Activation; Immunohistochemistry; Inflammation; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Motor Activity; NADPH Oxidases; Neurons; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinson Disease, Secondary; Paroxetine; Peroxidase; Reverse Transcriptase Polymerase Chain Reaction; Substantia Nigra; Tumor Necrosis Factor-alpha | 2010 |
Paroxetine-molindone interaction.
Topics: Aged; Basal Ganglia Diseases; Delusions; Depressive Disorder; Drug Interactions; Female; Humans; Molindone; Parkinson Disease, Secondary; Paroxetine | 1995 |